论文部分内容阅读
目的:观察分析肝动脉化疗联合艾迪注射液治疗肝转移瘤的临床评价指标。方法:将102例肝转移瘤患者随机等分为3组:A组单纯接受肝动脉一次性冲击化疗;B组肝动脉化疗后,给予静脉滴注艾迪注射液;C组肝动脉化疗后,肝动脉内留置导管持续灌注艾迪注射液。比较3组经6个治疗周期前后肿瘤的大小、T细胞亚群情况以及化疗药物的胃肠道反应、骨髓抑制情况。结果:3组有效率分别为41.2%,47.1%,67.6%,B组和A组,B组与C组比较无明显差别(P>0.05),C组与A组比较有显著性差异(P<0.05);T细胞亚群改善和化疗药物的不良反应发生率,B、C两组之间无差异(P>0.05),B、C组分别与A组比较差别明显(P<0.05)。结论:艾迪注射液联合化疗药物肝动脉持续灌注治疗肝转移瘤能够提高近期疗效,可能优于静脉滴注,艾迪注射液起到为协同、增效、减毒及提高免疫力的作用。
Objective: To observe and analyze the clinical evaluation indexes of hepatic artery chemotherapy combined with Aidi injection in the treatment of liver metastases. Methods: A total of 102 patients with liver metastases were randomly divided into 3 groups: group A received single-pass chemotherapy with hepatic artery; group B received intravenous injection of adi injection after hepatic artery chemotherapy; group C received hepatic artery chemotherapy, Hepatic artery indwelling catheter continuous infusion of Aidi injection. The size of tumor, the T cell subsets, and the gastrointestinal reactions and myelosuppression of chemotherapy drugs were compared between the 3 groups after 6 cycles of treatment. Results: The effective rates of the three groups were 41.2%, 47.1% and 67.6% respectively. There was no significant difference between group B and group A (P> 0.05). There was significant difference between group C and group A (P <0.05). There was no significant difference between groups B and C (P> 0.05). There was a significant difference between group B and group C and group A (P <0.05). Conclusion: Aidi injection combined with continuous hepatic artery perfusion therapy for liver metastases can improve the short-term curative effect, which may be superior to intravenous drip. Aidi injection can play a synergistic, synergistic, attenuating and immune enhancing effect.